6IVA Stock Chart & Stats
€3.74
-€0.06(-1.58%)
At close: 4:00 PM EDT
€3.74
-€0.06(-1.58%)
Day’s Range― - ―
52-Week Range€2.68 - €6.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€672.09M
Enterprise Value€920.42
Total Cash (Recent Filing)€99.27M
Total Debt (Recent Filing)€59.40M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 31, 2027EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-29.92
Price to Sales (P/S)193.76
P/FCF Ratio-8.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.90Price Target Upside271.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.7
Revenue Forecast (FY)€6.65M
Bulls Say, Bears Say
Bulls Say
Phase III Catalyst And Development ProgressCompletion of the final patient visits keeps Inventiva on a defined path toward a major phase III readout within the next several months. A successful result could support the planned regulatory filing and materially advance lanifibranor from clinical development toward commercialization.
Encouraging Efficacy And Differentiated MechanismThe phase II-B results provide clinical support for lanifibranor’s potential efficacy in MASH, while its balanced modulation of all three PPAR isoforms offers a differentiated therapeutic approach. These features may strengthen positioning if the phase III trial confirms the earlier findings.
Regulatory Designations Support Development PriorityBreakthrough Therapy and Fast Track designations indicate that the FDA has recognized lanifibranor’s potential to address an important medical need. They can facilitate interactions and expedite development planning, improving regulatory engagement as Inventiva approaches its planned filing window.
Bears Say
Severe Revenue Deterioration And Persistent LossesThe sharp revenue decline and exceptionally large losses show that Inventiva has not yet established recurring commercial economics. Continued dependence on development financing leaves profitability highly contingent on clinical success, regulatory progress, and eventual product commercialization.
Persistent And Increasing Cash BurnOngoing negative operating and free cash flow means the company must continue consuming capital to fund research and clinical programs. The higher 2025 operating burn increases dependence on financing and reduces resilience if development timelines extend or funding conditions become less favorable.
Negative Equity And Rising Debt Weaken Financial FlexibilityNegative equity combined with materially higher debt reflects a weakened capital structure and limits financial flexibility. This increases the company’s reliance on additional financing, while debt obligations can constrain spending choices and intensify pressure to achieve clinical and regulatory milestones.
Inventiva News
6IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was €2.68 and its highest was €6.20 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is €672.09M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Mar 31, 2027 which is in 183 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 28, 2026. The company reported -€0.177 earnings per share for the quarter, beating the consensus estimate of -€0.336 by €0.159.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.31.
How many shares outstanding does Inventiva have?
Inventiva has 236,280,200 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -€0.177 in its last earnings report, beating expectations of -€0.336. Following the earnings report the stock price went down -6.809%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in DE:6IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.90 (271.64% Upside)
€13.90 (271.64% Upside)
Blogger Sentiment
Bullish
DE:6IVA Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
37.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inventiva
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
6IVA Company Deck
6IVA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly focused on progress toward the NATiV3 phase III readout, positive phase II-B efficacy, preparation for potential regulatory and commercial milestones, and a strengthened financial position. Management also addressed known tolerability considerations, including weight gain, edema, and hemoglobin decline, while withholding additional blinded phase III safety and efficacy details. The positive development, financing, and preparation updates significantly outweighed the disclosed challenges and uncertainties.View all DE:6IVA earnings summaries6IVA Stock 12 Month Forecast
Average Price Target
€13.90
▲(271.64% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―